The GLP-1 Pill vs. The GLP-1 Shot: We Ran the Numbers on 72 Weeks of Real Data
Foundayo delivers 11% weight loss. Zepbound delivers 21%. But a drug you take beats a drug you quit. We ran every number that matters — including the ones the clinical trials don't capture.
The 72-Week Data, Side by Side
Until Foundayo's approval on April 1, 2026, the "oral vs. injectable" debate was academic. Now it's the most consequential choice a new GLP-1 patient will make. We pulled the clinical trial numbers from ATTAIN-1 (Foundayo), STEP-1 (Wegovy), and SURMOUNT-1 (Zepbound) and ran them head-to-head.
| Outcome (at 72 weeks) | Foundayo (oral, 36mg) | Wegovy (injection, 2.4mg) | Zepbound (injection, 15mg) |
|---|---|---|---|
| Mean weight loss | 11.2% | 15.6% | 20.9% |
| Placebo weight loss | 2.1% | 2.4% | 3.1% |
| Net drug effect | 9.1% | 13.2% | 17.8% |
| Patients losing ≥10% | ~45% | ~60% | ~73% |
| Patients losing ≥20% | ~15% | ~32% | ~50% |
On pure efficacy, injectables win and it's not particularly close. Zepbound delivers nearly double the net weight loss of Foundayo. But clinical trials don't capture the full picture.
The Adherence Factor Nobody's Measuring Yet
Here's the number that could flip this calculation: real-world adherence. Studies consistently show that oral medications have higher long-term compliance than injectables across therapeutic categories. A commonly cited estimate is that ~50% of GLP-1 injection users discontinue within 12 months.
A drug that delivers 11% weight loss but gets taken for 3 years produces more total benefit than a drug that delivers 21% weight loss but gets abandoned at month 8. We don't have head-to-head adherence data for Foundayo vs. injectables yet — those studies will take 1–2 years. But the structural advantages are significant:
| Adherence Factor | Foundayo (Pill) | Injectables |
|---|---|---|
| Needle aversion barrier | Eliminated | Present for many patients |
| Refrigeration needed | No | Yes (pre-use) |
| Travel compatibility | Easy | Requires cold storage and supplies |
| Social stigma / privacy | Pill is invisible | Injection supplies visible |
| Dosing flexibility | Any time, any meal status | Weekly schedule to maintain |
The Brain Science Angle
There's another factor most comparisons miss entirely. NIH-funded research published in Nature in May 2026 found that oral small-molecule GLP-1s like orforglipron reach the brain's central amygdala — a reward center that injectable peptide GLP-1s don't directly access. This means oral GLP-1s suppress both hunger-driven eating (like injectables) AND pleasure-driven eating (a bonus). For patients whose primary challenge is emotional eating and food cravings rather than physical hunger, this could be a significant differentiator.
The Cost Equation
Foundayo's retail pricing hasn't been fully disclosed yet (LillyDirect began shipping April 6, 2026), but all three are included in the Medicare GLP-1 Bridge at $50/month starting July 1. For self-pay patients, compounded semaglutide and tirzepatide remain available through telehealth providers at $99–350/month, though the FDA's proposal to permanently ban compounding (comment period through June 29, 2026) could eliminate those options.
Sources
- ATTAIN-1 trial data: Pharmacy Times, April 2026. pharmacytimes.com
- STEP-1 and SURMOUNT-1 published trial data via NEJM.
- Godschall EN, et al. "A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs in Mice." Nature, 2026. nih.gov
- BMJ meta-analysis on GLP-1 discontinuation and weight regain. January 2026. bmjgroup.com